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Future therapeutic strategies in inflammatory cardiomyopathy:
insights from the experimental autoimmune myocarditis model
Abstract
Inflammatory cardiomyopathy is a common cause of heart failure developing on a basis of cardiac
inflammation. Cardiac inflammation - or myocarditis - is usually triggered by infections or cardiac
damage of any cause. Experimental autoimmune myocarditis refers to a CD4(+) T cell-mediated mouse
model of inflammatory cardiomyopathy. So far, the experimental autoimmune myocarditis model
helped us to understand the role of various chemokines, cytokines, and cell subsets in the progression of
inflammatory heart disease. Here, we review the current therapeutic options for inflammatory
cardiomyopathy, and delineate potential future treatment approaches from the most recent mechanistic
insights given by the experimental autoimmune myocarditis model.
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Abstract 
Inflammatory cardiomyopathy is a common cause of heart failure developing 
on a basis of cardiac inflammation. Cardiac inflammation - or myocarditis - is 
usually triggered by infections or cardiac damage of any cause. Experimental 
autoimmune myocarditis refers to a CD4+ T cell-mediated mouse model of 
inflammatory cardiomyopathy. So far, the experimental autoimmune myocarditis 
model helped us to understand the role of various chemokines, cytokines, and cell 
subsets in the progression of inflammatory heart disease. Here, we review the 
current therapeutic options for inflammatory cardiomyopathy, and delineate 
potential future treatment approaches from the most recent mechanistic insights 
given by the experimental autoimmune myocarditis model.  
- 2 - 
Clinical significance of iCM 
 Inflammatory cardiomyopathy (iCM) refers to acquired cardiac dysfunction due 
to chronic myocardial inflammation. This definition [1] supports a pathogenetic concept, 
in which symptomatic or asymptomatic myocarditis triggers a complex system of 
interactions of host, environmental, and agent related factors for the later development of 
dilated cardiomyopathy. In Europe and North America iCM most often results from 
infections with enteroviruses such as coxsackievirus B3 (CVB3) [2-6], adenoviruses [6], 
or parvovirus B19 [7,8]. In South America, infections with protozoan Trypanosoma cruzi 
(called Chagas disease) are the most common cause of inflammatory heart disease [9]. 
Accordingly, recent findings suggest myocardial viral genome persistence in more than 
67% of patients with iCM. Phenotypically, iCM can present as dilated cardiomyopathy 
characterized by myocardial dilation and ventricular dysfunction. In addition, 
epidemiologic data suggest that iCM is an important cause of heart failure and sudden 
death in children and young patients [10-12].  
According to the “Dallas” criteria, a definition of myocarditis requires the 
presence of inflammatory infiltrates with necrosis and/or degeneration of adjacent 
cardiomyocytes [13]. Presence of inflammatory infiltrates in the absence of apparent 
myocyte damage is classified as borderline myocarditis [13]. The transient appearance 
and the often patchy distribution of heart infiltrating cells explains the low sensitivity of 
endomyocardial biopsies in the work-up of patients with suspected inflammatory heart 
diseases.  
From a clinical point of view, it is important to emphasize that many patients with 
myocarditis show minimal symptoms only, or are entirely asymptomatic. Nevertheless, 
these patients may develop iCM on follow-up. Patients with symptomatic and chronic 
lymphocytic myocarditis, on the other hand, usually show a progressive disease course 
and develop iCM with significant mortality [14]. Interestingly, the few patients, which 
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develop fulminant myocarditis with rapid onset heart failure and/or severe arrhythmias 
have a favorable long-term outcome [4,14].  
 
iCM and autoimmunity  
Cardiotropic viruses rapidly lyse cardiomyocytes in tissue cultures and/or damage 
them by cleaving the cytoskeleton [15]. In addition, ultrastructural studies of myocardial 
tissues from mice infected with cardiotropic viruses provide evidence for ongoing 
apoptosis-mediated cell death of virus-infected cardiomyocytes [16-18]. Despite the 
persistence of viral genomes in infected mouse hearts, the susceptibility to develop 
chronic myocarditis varies among different mouse strains. This observation leads to the 
conclusion that the presence of the virus is not the only factor promoting the development 
of inflammatory cardiomyopathy [19]. Indeed, clinical observations suggest that 
autoimmune mechanisms are critically involved in development and progression of the 
disease. Accordingly, 30% of patients with myocarditis and dilated cardiomyopathy 
develop heart-specific autoantibodies against cardiac myosin-α and –β, or cardiac 
troponin I [20-23]. In addition, there is a weak albeit significant association of specific 
HLA patterns with iCM [21,24].  
Observations on animal models further supported the view that autoimmune 
mechanisms contribute to disease progression in virus-triggered iCM. Schwimmbeck et 
al. showed, for example, that transfer of mononuclear blood cells from patients with iCM, 
but not from patients with ischemic heart disease, induces myocarditis in SCID mice 
[25,26]. Lodge et al. induced myocarditis in BALB/c and DBA/2 mice by injections of 
cardiotropic viruses [27]. The disease course of CVB3 virus-infected BALB/c mice 
revealed a biphasic inflammation pattern characterized by an early acute stage 7-14 days 
after inoculation followed by a chronic stage of autoimmune mediated low-grade 
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inflammation progressing to end stage heart failure [19,28,29]. Interestingly, the 
development of chronic myocarditis after virus infection was associated with polyclonal 
heart-specific autoantibody responses and the expansion of heart-specific, autoaggressive 
T cells [19,30,31]. Together, these findings clearly argue that heart-specific 
autoimmunity plays an important role in the chronic phase of viral myocarditis, and most 
likely also in the progression of iCM in humans. 
 
The experimental autoimmune myocarditis model 
The idea that the chronic phase of myocarditis reflects virus-triggered, heart-
specific autoimmunity led to the development of the experimental autoimmune 
myocarditis (EAM) model. In the EAM model, susceptible rats or mice were either 
immunized with cardiac self-antigens together with a non-specific adjuvant or were 
injected with activated dendritic cells (DCs) loaded with cardiac α-myosin peptides [32-
34]. Cardiac α-myosin, peptides derived from cardiac α-myosin, or cardiac troponin I 
can be used to induce EAM in BALB/c and A/J mice [32,35-37]. EAM development is 
generally associated with elevated titers of heart-specific autoantibodies [32], but the 
disease is T cell mediated – at least in rats and most of the susceptible mouse strains - 
depending on the induction/expansion of heart specific, autoreactive CD4+ T cells. In the 
BALB/c mouse strain, the pathogenic heart disease mediating CD4+ T cells belong to a 
specific subset of IL-17 producing helper cells, i.e. Th17 cells [38]. In the EAM model, 
histologic myocarditis severity peaks three weeks after the first immunization. Later on, 
inflammation largely resolve, but the process of pathological remodelling continues and 
many animals develop ventricular dilation and heart failure on follow-up [34,39]. 
Despite the fact that the EAM models are rather artificial, they offer the great 
advantage to study disease pathogenesis and autoimmune mechanisms in vivo in the 
absence of an infective agent. In addition, the immunization with myosin peptide-loaded, 
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activated DCs offers a useful tool to dissect the role of antigen-presenting cells (APCs) 
and effector cells while studying disease mechanisms. From the EAM model we can not 
only learn about autoimmune mechanisms contributing to disease development, but the 
model also allows us to study the pathophysiology of inflammatory heart disease and 
helps us in the design of novel, immunomodulating treatment strategies. In addition, the 
EAM model might offer a potential tool to refine the diagnostic accuracy of currently 
available and future imaging modalities in iCM. 
 
Current treatments for iCM 
Over the last years therapeutic options for inflammatory heart disease was rather 
supportive facing the clinical syndrome of heart failure or arrhythmias [4] and included 
basic heart failure medications with angiotensin-converting enzyme inhibitors or 
angiotensin-receptor blocking agents, diuretics, aldactone and betablockers [40-43]. In 
addition, all patients with persistently impaired cardiac ejection fraction and/or life 
threatening arrhythmias take survival advantage from implantable cardiac defibrillators. 
In severe and rapidly progressive cases, however, heart transplantation still represents the 
only treatment option. 
 As mentioned above, myocarditis and dilated cardiomyopathy are often associated 
with viral infection. Thus, the question arises whether clearance of persistent viral 
infections by stimulation of the antiviral innate immune response slows the progression 
of iCM. Indeed, data from a phase II study suggest that IFN-β is effective in patients with 
left ventricular dysfunction and biopsy proven myocardial persistence of enteroviral or 
adenoviral genome [44]. The efficacy of anti-viral treatments, however, may depend on 
the virus. It is therefore of up most importance to clarify the viral etiology, establishing a 
reasonable diagnostic approach, before larger prospective clinical studies can be planned 
[45]. 
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 The idea that autoimmune mechanisms play a role in the pathogenesis of 
myocarditis and postviral cardiomyopathy raised the question of a potential beneficial 
effect of immunosuppressive treatments in affected patients. Unfortunately, large 
randomized clinical trials failed to prove a survival advantage for immunosuppression 
[46,47]. Nevertheless, several recently published studies suggested beneficial effects of 
immunosuppressive treatment for certain subgroups of patients. Immunosuppressive 
treatment was effective in improving ejection fraction in patients with active lymphocytic 
myocarditis and undetectable viral genomes [48] or in patients with up-regulation of 
activation markers in heart biopsy samples [49]. Immunosuppressive treatments also 
appear as a helpful option in patients with giant-cell myocarditis [50], and celiac disease-
associated myocarditis [51]. 
 
Future strategies: targeting innate mechanisms of immune activation 
Treatment of iCM requires silencing of the persistent heart-specific inflammation. 
In the EAM model, the development of inflammatory infiltrates depends on the 
sequential activation of self-antigen presenting DCs, the expansion of self-pathogenic T 
cells, and the accumulation of monocytes/macrophages within the heart [33,52-55]. DCs 
represent major of APCs representing scavengers for cellular debris and key players 
balancing the immune responses against foreign antigens and the maintenance of 
peripheral self-tolerance [56,57]. If DCs, which took up cardiac self-antigens, get 
activated through Toll-like receptors (TLRs) beyond a genetically and individually 
determined threshold level, autoimmune heart disease may develop [34,54,58]. From this 
point of view, targeting innate activation pathways, such as TLR signalling, might protect 
from heart-specific autoimmunity. Indeed, various compounds blocking TLR signalling 
had already been tested for drug development in cardiovascular diseases and are 
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potentially available [59]. But what is the role of TLR-mediated non-specific activation 
during the progression of acute myocarditis to heart failure and pathological remodelling? 
Several lines of evidence suggest that TLR-mediated pathways might contribute to 
fibroblast proliferation [60] and to the activation of endothelia and tissue resident APCs 
[61-63]. These effects are mediated either directly or by the induction of genes encoding 
pro-inflammatory cytokines and mediators. We believe that the EAM model and gene-
targeted mice provide a useful tool to address the role of specific TLR-mediated 
pathways in disease progression and to define rationale treatment strategies.  
 
Development of therapeutic strategies: targeting specific cytokines and mediators  
In clinical practice, a diagnosis of myocarditis usually results from either 
symptoms and signs of impaired heart function, or signs of pericardial involvement, such 
as pain [4]. Theoretically, specific cytokine targeting should result in treatment strategies 
with minimal side effects. Unfortunately, cytokines, which are critical for disease 
development, are not necessarily those, which promote heart failure progression 
accounting for symptomatic disease. Nevertheless, the EAM model might help us to 
define the specific role of different cytokines at the various time points of iCM 
progression. Both, induction and progression of iCM depend on a complicated balance of 
many pro- and anti-inflammatory cytokines. In the EAM model, the role of the cytokines 
TNF-α, IFN-γ, IL-1, IL-4, IL-6, IL-10, IL-12, IL-13, IL-17, and IL-23 had been 
elucidated [64-71]. So far, however, only TNF targeting has been evaluated clinically. 
TNF-α is a key pro-inflammatory cytokine in autoimmune myocarditis 
development. Mice lacking the TNFRp55 are protected from EAM [64], whereas heart 
specific over-expression of TNF-α promotes myocarditis and cardiomyopathy [72]. 
Indeed, it had been hypothesised that TNF-α mediates activation of tissue resident DCs 
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[35]. In addition, TNF-α directly affects cardiac contractile function [73]. Not 
surprisingly, patients with advanced heart failure show increased TNF-α serum levels 
[74]. Unfortunately, two large-scale, randomized clinical trials evaluating the TNF-α-
antagonists Etanercept and Infliximab for the treatment of dilated cardiomyopathy had to 
be stopped early because of excessive mortality in the treatment group [75,76]. 
IL-10 represents another pleiotropic cytokine with immunomodulatory and even 
immunosuppressive properties. In the context of inflammatory heart disease models, IL-
10 or IL-10 producing T cells protected against viral and experimental autoimmune 
myocarditis in mice [71,77,78]. Furthermore, anti-IL-10 antibody treatments prevented 
the development of heart specific tolerance against α-myosin/CFA immunization in mice 
[79]. These experimental findings, however, somehow contrasted the observation that 
elevated IL-10 serum levels predicted poor short-term prognosis in survival in patients 
with acute myocarditis [80].  
The Renin-Angiotensin system plays an important role in the vicious cycle 
between maladaptation and heart failure progression. Accordingly, angiotensin-
converting enzyme inhibitors and AT1 receptor blockers reduce mortality rates in patients 
with chronic heart failure [81,82]. Angiotensin II, however, is not only a vasocontrictor 
and mediator of sodium retention but plays also an important role as an inflammation-
modulating peptide [83]. Accordingly, it mediates vascular inflammation and chemotaxis 
of inflammatory cells and promotes myocyte growth changes. In experimental viral 
myocarditis, AT1 receptor signalling is involved in the NF-κB-dependent release of pro-
inflammatory cytokines, such as IL-1 and TNF-α [84]. Furthermore, administration of 
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AT1 receptor blockers or angiotensin-converting enzyme inhibitors reduces myocardial 
damage in experimental myocarditis [85,86]. 
 Inhibitory effect on the cytokine production can be achieved also with 
phosphodiesterase inhibitors, such as Pimobendan. In a model of viral myocarditis, for 
example, Pimobendan reduced the intracardiac production of IL-1β, IL-6, TNF-α and 
nitric oxide in a NF-κB-dependent pathway [87,88]. Similarly, administration of PPAR-γ 
activators mediated cardioprotective effects by interfering with the NF-κB-dependent 
pathway in a model of EAM in rats [89]. 
 Another option to block excessive cytokine production in the heart is to prevent 
the migration of inflammatory cells. Chemokines play a critical role in basal and 
inflammation-triggered trafficking of bone marrow-derived cells [90]. Indeed, elevated 
levels of CCL chemokines - potent chemoattractants for mononuclear cells - are a 
prominent feature in experimental myocarditis [37,91,92]. Accordingly, blocking CCL 
chemokines significantly reduces myocarditis severity and intracardiac cytokine release 
in the EAM model [93,94]. Much less is known regarding the role of CXCL chemokines 
in EAM. In the context of ischemic heart disease, it was shown that stromal cell-derived 
factor-1 (SDF-1)/CXCL-12 induces the chemotaxis of hematopoietic progenitors and is 
involved in heart repair and remodelling after myocardial infarction [95,96]. Unpublished 
observations from our laboratory suggest important roles of SDF-1 and CXCR-4 (SDF-1 
receptor)-expressing cells in autoimmune myocarditis. 
 
Future strategies: targeting the heart-specific T cell response and auto-antibodies 
 Autoreactive T cells are involved in the autoimmune process contributing to iCM 
progression. During the past years, two distinct CD4+ T helper cell subsets have been 
defined according to their major cytokine production pattern: IFN-γ producing Th1 cells, 
and Th2 cells releasing IL-4. In the EAM model, the majority of the cells infiltrating the 
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inflamed heart are monocytes/macrophages, suggesting a correlation between 
inflammation and Th1 cells [97]. Surprisingly, however, loss of IFN-γ or its receptor 
markedly increased myocarditis severity, implying that the characteristic Th1 cytokine 
IFN-γ is a negative regulator for EAM [66,97]. In addition, mice lacking T-bet, a T-box 
transcription factor essential for Th1 lineage differentiation, show enhanced myocarditis 
severity [38]. Recent data finally revealed that IL-1, IL-6, and IL-23 promote the 
expansion and survival of a distinct CD4+ T cell population characterized by IL-17 
production, which develop as a Th1 and Th2 cell-independent lineage [98-101]. 
In EAM, heart-infiltrating α-myosin-specific CD4+ Th17 cells are pathogenic and 
cause ongoing inflammation in the myocardium. In fact, adoptive transfer of α-MyHC-
specific CD4+ Th17 induced autoimmune myocarditis in healthy mice [55]. In addition, 
mice with ongoing autoimmune myocarditis treated with serial injections of antibodies 
blocking IL-17 or with active vaccination both ameliorated disease severity, showing a 
marked reduction of heart-infiltrating cells [55,102]. In EAM, CD11b+ 
monocytes/macrophages represent the major heart-infiltrating cell population [34]. The 
observation that CD11b+ monocytes/macrophages recruited into the heart are drastically 
reduced after serial injections of IL-17-depleting antibodies in mice with EAM, suggests 
a direct pathogenic role of IL-17 in the EAM model [55]. Interestingly, recent findings 
suggest that heart-infiltrating CD11b+ cells are not only the major substrate of 
inflammation in EAM but play also a crucial role in an IFN-γ-dependent negative 
feedback mechanism confining autoreactive T cells [55]. Mechanistically, IFN-γ induces 
NOS2 up-regulation in monocytes. NOS2 up-regulation promotes local release of nitric 
oxide, which has been recognized as a short living mediator of reversible T cell growth 
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arrest at physiological levels. This inflammation limiting mechanism helps to avoid 
extensive and progressive damages in the inflamed organs.  
T cell-directed treatment strategies could specifically target pathogenic, 
autoreactive T cell subsets. Recognizing the subtle balance between different T cell 
subsets regulating each other could also help in the development of vaccination strategies 
preventing heart-specific immunity. 
Insights from various autoimmune disease models suggest that the expansion of 
autoreactive T cells is regulated by naturally occurring regulatory T cells (Treg). A role 
for Treg has also been suggested in the context of EAM, and the cytokines IFN-γ, IL-10 
and TNF-α might be involved in the activation and function of Treg [79,103-105]. Ono et 
al. provided direct evidence that GITRhigh expression characterizes a CD4+ T cell 
population with regulatory capacity in the EAM model. Interestingly, the GITRhigh 
expressing regulatory CD4+ T cell subset included both, CD25+ and CD25- cells. [105]. 
Despite the current lack of knowledge in this field, modulation of Treg might become a 
powerful tool to control heart-specific autoimmunity in the future. 
T helper cells are also involved in the generation of the humoral immune response 
leading to autoantibody production. Depending on the genetic constellation, 
autoantibodies can be important for iCM development. Whereas autoantibodies are not 
required to induce autoimmune myocarditis in BALB/c mice, transfer of heart-specific 
antibodies mediates cardiac inflammation in DBA/2 mice [106,107]. Nevertheless, 
autoantibodies can directly contribute to cardiac dysfunction. In mice lacking the 
programmed cell death-1 (PD-1) immunoinhibitory co-receptor antibodies against cardiac 
troponin I promote heart failure development [108]. Accordingly, the removal of 
autoantibodies by immunoadsorption techniques might offer a potential therapeutic 
option for patients with iCM. In fact, plasmapheresis/affinity adsorption improved short-
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term hemodynamics as well as long-term follow-up in selected patients with idiopathic 
dilated cardiomyopathy [109,110]. These data, however, are preliminary and larger, 
controlled studies are necessary to confirm a potential beneficial effect of 
immunoadsorption in this setting. 
 
Therapeutic strategies: targeting pathological remodelling 
Viral infections and the resulting inflammation promote cardiac tissue destruction 
and heart failure development. Suppressing inflammation is one potential treatment 
strategy for iCM. To really improve cardiac function and to replace non-functional tissue, 
dead and apoptotic cardiomyocytes need to be replaced. In mammals, cardiomyocytes 
rarely divide after organ injury [111], and heart-resident stem cells, repopulate, if at all, 
destroyed cardiomyocytes only insufficiently [112]. Exogenous interventions are 
therefore necessary to improve cardiac function. One exciting therapeutic option is to 
specifically activate/promote already existing regenerative mechanisms in vivo. Recent 
data from rat model of myocardial infarction studies showed that stimulation of 
cardiomyocytes proliferation with periostin improves ventricular remodelling and 
myocardial function [113].   
Another, extensively studied option for cardiac regeneration is cell-based therapy. 
Optimal candidates for this therapy are endogenous cardiac stem cells (CSCs) with their 
self-renewal potential and ability to differentiate into cardiomyocytes [114,115]. The 
minimal risk of immune rejection and teratoma formation together with the natural 
capacity for cardiomyocyte differentiation is an advantage of CSCs, but definitive CSC-
specific markers and standardized protocols for isolation and expansion of these cells are 
lacking [112]. Cells with CSC-like properties can also be isolated and expanded from 
human myocardial biopsy samples [116], but no clinical data are available yet. In 
addition, fundamental questions regarding the efficacy of proliferation and differentiation 
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capacity, survival, functional integration and long-term stability have not been answered 
yet. 
Over past two decades, pluripotent embryonic stem (ES) cells with their ability to 
differentiate into practically all cell types of mammalian body (including functional 
cardiomyocytes) represented a great hope in regenerative medicine [117]. Differentiated 
ES cells can survive and improve heart function if delivered to the myocardium with pro-
survival factors [118]. Additionally, ES cells can be generated in practically unlimited 
number, but are facing ethical concerns and are at the greatest risk of teratoma formation 
and immune rejection [119]. Use of autologous cells can be applicable, if new technology 
of reprogramming fibroblast into ES-like cells becomes safe, reproducible and 
standardized for human cells [120]. So far, all these barriers prevented experimental use 
of ES cells in clinical trials. 
Other candidates for cell-based therapy are hematopoietic stem or progenitor 
cells. Despite several years of intensive research, the differentiation potential of bone 
marrow progenitor cells into cardiomyocytes is still controversial [121,122]. Most of 
clinical studies report either small or no benefits for hematopoietic stem cell therapies in 
heart disorders [112,123], and the mechanisms explaining such minimal effects are still 
unknown. Nevertheless, repopulation of functional cardiomyocytes seems to be highly 
unlikely. Similarly, cell-based therapy with endothelial progenitors and mesenchymal 
stem cells (MSCs) improve cardiac function. Mechanistically, these effects are supposed 
to be mediated by paracrine delivery of growth factors and promotion of angiogenesis, 
rather than cardiomyocyte differentiation [123,124].  
A growing body of evidence indicate that MSCs also possess immunomodulatory 
properties [125]. In vitro data suggest that MSCs affect the function of APCs, B cells, NK 
cells and T cells [126]. Immunosuppressive effects of MSCs were already reported in 
graft-versus-host disease and for experimental autoimmune encephalomyelitis [127,128]. 
In our laboratory, we have recently demonstrated that cardiac or bone marrow CD133+ 
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cells ameliorate EAM [129]. Because of their immunomodulating effects, stem and 
progenitor cell-based treatments appear as a particularly interesting option for iCM 
treatment. 
EAM is a particularly helpful model to address the therapeutic potential of 
stem/progenitor cell-based therapies because it allows us to investigate both, their anti-
inflammatory potential and their reparative capacity in iCM.  
 
Future strategies: improving the diagnostic accuracy of imaging modalities 
The EAM model greatly advanced our knowledge on the physiopathology of 
inflammatory heart diseases. In addition, and as outlined above, the EAM model 
represents a helpful tool for the development of novel treatment strategies. Because of its 
simplicity and reproducibility the EAM model might also be of help in the refinement of 
currently available or future imaging modalities [130]. Clinically, myocarditis or iCM 
presents with a wide spectrum of symptoms and it is difficult to determine the true 
incidence of myocarditis in humans. Given the low sensitivity and the procedural risks 
associated with endomyocardial biopsy, there is a need for sensitive and specific non-
invasive modalities. So far, the murine myocarditis model helped to develop non-invasive 
imaging tests based on the detection of myocyte necrosis using Indium-111 anti-myosin 
antibodies [131]. Other studies suggested a diagnostic role for radio-labelled anti-tenascin 
C antibodies and SPECT using a rat autoimmune myocarditis model [132].  
Taken together, various non-invasive diagnostic approaches have already been 
evaluated in small studies, but the relatively low numbers of patients, the variability in 
clinical disease course, and the lack of a reliable “Gold-standard” still put some question 
marks on their diagnostic accuracy [133]. This holds even true for cardiac magnetic 
resonance imaging, which is on the way to become the standard diagnostic test of choice 
in suspected myocarditis [134,135]. In this context, EAM model might be particularly 
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helpful in correlating the morphology of cardiac inflammation and the disease course 
with specific findings in non-invasive diagnostic tests.  
 
Conclusive remarks 
 Clinical studies and animal models greatly expanded our knowledge on the 
pathogenesis of iCM. Future studies will address therapeutic strategies targeting different 
stages of disease development focusing on the elimination of the infecting agent, 
inhibition of the heart-specific autoimmune response, reduction of local inflammation 
and inflammatory-associated tissue remodelling, and - hopefully - repair of damaged 
myocardium. So far, however, most of the suggested approaches were addressed in 
animal studies only. Despite their advantage in creating new and promising perspectives, 
data from animal models must be estimated with caution. Therefore, animal and clinical 
studies should be designed in parallel to speed up our progress in the development novel 
therapeutic strategies. 
 
Figure legend 
The EAM model provides insights into the key mechanisms of inflammatory heart 
disease development. Cardiac damage results in release of heart-specific self-antigens. In 
the presence of non-specific adjuvants, such as microbial products or heat-shock proteins, 
APCs internalizing cardiac self-antigens get activated beyond a threshold level and 
promote heart-specific autoimmunity. In the EAM model, heart-specific autoimmunity is 
mediated by IL-17 producing CD4+ T cells and depends critically on specific chemokines 
and cytokines. These cytokines/chemokines might become promising targets for the 
development of novel treatment strategies against iCM.  
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